Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avalon Pharmaceuticals has announced the initiation of the next phase in its drug discovery collaboration with Novartis that aims to discover small molecule therapeutic compounds targeted against a pathway selected by Novartis.
Subscribe to our email newsletter
AvalonRx, Avalon’s proprietary drug discovery platform, was used to screen, identify and characterize compounds from Novartis’s proprietary compound library. Avalon said that candidate hit compounds were successfully identified by monitoring gene expression changes of a transcriptional signature reflecting disruption of the selected pathway.
The parties have agreed to initiate characterization of the identified compounds which triggers an undisclosed payment to Avalon for research support under the terms of the agreement.